
What is claimed is:

1. A pharmaceutical composition comprising Compound 1:



1,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent, wherein the carrier or diluent is mannitol, and wherein the amount of mannitol is from 80 to 98 % w/w.

~~2. The pharmaceutical composition of claim 1, wherein the carrier or diluent is mannitol.~~

~~3.~~2. The pharmaceutical composition of claim ~~2~~ 1, further comprising a glidant, an acidifier, a lubricant, or a mixture thereof.

~~4.~~3. The pharmaceutical composition of claim ~~2~~ 1, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from ~~about~~ 0.05 to ~~about~~ 3 % w/w; 2) mannitol at an amount of from ~~about~~ 80 to ~~about~~ 98 % w/w; 3) a glidant at an amount of from ~~about~~ 0 to ~~about~~ 10 % w/w; 4) an acidifier at an amount of from ~~about~~ 0 to ~~about~~ 6 % w/w; and 5) a lubricant at an amount of from ~~about~~ 0 to ~~about~~ 8 % w/w.

~~5.~~4. The pharmaceutical composition of claim 3~~4~~, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

~~6.~~5. The pharmaceutical composition of claim 4~~5~~, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

~~7.~~6. The pharmaceutical composition of claim ~~4~~5, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at ~~approximately~~ 14.6, 18.2, and 18.3º 2θ ± 0.2 2θ.

~~8.~~7. The pharmaceutical composition of any one of claims ~~3~~4 to ~~6~~7, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from ~~about~~ 0.1 to ~~about~~ 1.5 % w/w.

~~9.~~8. The pharmaceutical composition of claim ~~7~~8, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from ~~about~~ 0.13 to ~~about~~ 1 % w/w.

~~10.~~9. The pharmaceutical composition of any one of claims ~~3~~4 to ~~8~~9, wherein the amount of mannitol is from ~~about~~ 85 to ~~about~~ 95 % w/w.

~~11.~~10. The pharmaceutical composition of claim ~~9~~10, wherein the amount of mannitol is from ~~about~~ 90 to ~~about~~ 93 % w/w.

~~12.~~11. The pharmaceutical composition of any one of claims ~~3~~4 to ~~10~~11, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

~~13.~~12. The pharmaceutical composition of any one of claims ~~3~~4 to ~~11~~12, wherein the amount of the glidant is from ~~about~~ 0.25 to ~~about~~ 3 % w/w.

~~14.~~13. The pharmaceutical composition of claim ~~12~~13, wherein the amount of the glidant is from ~~about~~ 0.5 to ~~about~~ 2 % w/w.

~~15.~~14. The pharmaceutical composition of any one of claims ~~3~~4 to ~~13~~14, wherein the acidifier is fumaric acid.

~~16.~~15. The pharmaceutical composition of any one of claims ~~3~~4 to ~~14~~15, wherein the amount of the acidifier is from ~~about~~ 2 to ~~about~~ 5 % w/w.

~~17.~~16. The pharmaceutical composition of claim ~~15~~16, wherein the amount of the acidifier is ~~about~~ 3 % w/w.

~~18.~~17. The pharmaceutical composition of any one of claims 3~~4~~ to 16~~17~~, wherein the lubricant is stearic acid.

~~19.~~18. The pharmaceutical composition of any one of claims 3~~4~~ to 17~~18~~, wherein the amount of the lubricant is from ~~about~~ 2 to ~~about~~ 6 % w/w.

~~20.~~19. The pharmaceutical composition of claim 18~~19~~, wherein the amount of the lubricant is ~~about~~ 4 % w/w.

~~21.~~20. The pharmaceutical composition of claim 3~~4~~, comprising: 1) Compound 1 at an amount of ~~about~~ 0.13 % w/w; 2) mannitol at an amount of ~~about~~ 92.37 % w/w; 3) silica dimethyl silylate at an amount of ~~about~~ 0.5 % w/w; 4) fumaric acid at an amount of ~~about~~ 3 % w/w; and 5) stearic acid at an amount of ~~about~~ 4 % w/w.

~~22.~~21. The pharmaceutical composition of claim 20~~21~~, having a total weight of ~~about~~ 75 mg.

~~23.~~22. The pharmaceutical composition of claim 21~~22~~, which is contained in a size 4 capsule.

~~24.~~23. The pharmaceutical composition of claim 3~~4~~, comprising: 1) Compound 1 at an amount of ~~about~~ 0.5 % w/w; 2) mannitol at an amount of ~~about~~ 91.5 % w/w; 3) colloidal silicon dioxide at an amount of ~~about~~ 1 % w/w; 4) fumaric acid at an amount of ~~about~~ 3 % w/w; and 5) stearic acid at an amount of ~~about~~ 4 % w/w.

~~25.~~24. The pharmaceutical composition of claim 23~~24~~, having a total weight of ~~about~~ 100 mg.


~~26.~~25. The pharmaceutical composition of claim 24~~25~~, which is contained in a size 3 capsule.

~~27.~~26. The pharmaceutical composition of claim 3~~4~~, comprising: 1) Compound 1 at an amount of ~~about~~ 1 % w/w; 2) mannitol at an amount of ~~about~~ 90 % w/w; 3) colloidal silicon dioxide at an amount of ~~about~~ 2 % w/w; 4) fumaric acid at an amount of ~~about~~ 3 % w/w; and 5) stearic acid at an amount of ~~about~~ 4 % w/w.

~~28.~~27. The pharmaceutical composition of claim 26~~27~~, having a total weight of ~~about~~ 200 mg.

~~29.~~28. The pharmaceutical composition of claim 27~~28~~, which is contained in a size 2 capsule.

~~30.~~29. A~~The~~ pharmaceutical composition ~~of claim 1~~comprising Compound 1:



Compound 1,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent, wherein the carrier or diluent is a mixture of starch and lactose.

~~31.~~30. The pharmaceutical composition of claim 29~~30~~, further comprising a glidant, an acidifier, a lubricant, a disintegrant, or a mixture thereof.

~~32.~~31. The pharmaceutical composition of claim 29~~30~~, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from ~~about~~ 0.05 to ~~about~~ 3 % w/w; 2) a mixture of starch and lactose at an amount of from ~~about~~ 70 to ~~about~~ 90 % w/w; 3) a glidant at an amount of from ~~about~~ 0 to ~~about~~ 10 % w/w; 4) an acidifier at an amount of from ~~about~~ 0 to ~~about~~ 8 % w/w; 5) a lubricant at an amount of from ~~about~~ 0 to ~~about~~ 8 % w/w; and 6) a disintegrant at an amount of from ~~about~~ 0 to ~~about~~ 20 % w/w.

~~33.~~32. The pharmaceutical composition of claim 31~~32~~, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

~~34.~~33. The pharmaceutical composition of claim 32~~33~~, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

~~35.~~34. The pharmaceutical composition of claim 32~~33~~, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at ~~approximately~~ 14.6, 18.2, and 18.3º 2θ ± 0.2 2θ.

~~36.~~35. The pharmaceutical composition of any one of claims 31~~32~~ to 34~~35~~, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from ~~about~~ 0.1 to ~~about~~ 1.5 % w/w.

~~37.~~36. The pharmaceutical composition of claim 35~~36~~, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from ~~about~~ 0.13 to ~~about~~ 1 % w/w.

~~38.~~37. The pharmaceutical composition of any one of claims 31~~32~~ to 36~~37~~, wherein the starch is partially pregelatinized starch.

~~39.~~38. The pharmaceutical composition of any one of claims 31~~32~~ to 37~~38~~, wherein the lactose is anhydrous lactose.

~~40.~~39. The pharmaceutical composition of any one of claims 31~~32~~ to 38~~39~~, wherein the amount of the starch is from ~~about~~ 17 to ~~about~~ 22 % w/w, and the amount of the lactose is from ~~about~~ 53 to ~~about~~ 68 % w/w.

~~41.~~40. The pharmaceutical composition of any one of claims 31~~32~~ to 38~~39~~, wherein the amount of the mixture of starch and lactose is from ~~about~~ 75 to ~~about~~ 85 % w/w.

~~42.~~41. The pharmaceutical composition of claim 40~~41~~, wherein the amount of the starch is from ~~about~~ 18 to ~~about~~ 21 % w/w, and the amount of the lactose is from ~~about~~ 57 to ~~about~~ 64 % w/w.

~~43.~~42. The pharmaceutical composition of any one of claims 31~~32~~ to 38~~39~~, wherein the amount of the mixture of starch and lactose is from ~~about~~ 80 to ~~about~~ 82 % w/w.

~~44.~~43. The pharmaceutical composition of claim 42~~43~~, wherein the amount of the starch is from ~~about~~ 19 to ~~about~~ 20 % w/w, and the amount of the lactose is from ~~about~~ 61 to ~~about~~ 62 % w/w.

~~45.~~44. The pharmaceutical composition of any one of claims 31~~32~~ to 38~~39~~, wherein the weight ratio of the starch to the lactose is from ~~about~~ 1:2 to ~~about~~ 1:4.

~~46.~~45. The pharmaceutical composition of claim 44~~45~~, wherein the weight ratio of the starch to the lactose is from ~~about~~ 1:3 to ~~about~~ 1:3.3.

~~47.~~46. The pharmaceutical composition of any one of claims 31~~32~~ to 45~~46~~, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

~~48.~~47. The pharmaceutical composition of any one of claims 31~~32~~ to 46~~47~~, wherein the amount of the glidant is from ~~about~~ 0.25 to ~~about~~ 3 % w/w.

~~49.~~48. The pharmaceutical composition of claim 47~~48~~, wherein the amount of the glidant is from ~~about~~ 0.5 to ~~about~~ 1 % w/w.

~~50.~~49. The pharmaceutical composition of any one of claims 31~~32~~ to 48~~49~~, wherein the acidifier is fumaric acid.

~~51.~~50. The pharmaceutical composition of any one of claims 31~~32~~ to 49~~50~~, wherein the amount of the acidifier is from ~~about~~ 2 to ~~about~~ 6 % w/w.

~~52.~~51. The pharmaceutical composition of claim 50~~51~~, wherein the amount of the acidifier is ~~about~~ 4 % w/w.

~~53.~~52. The pharmaceutical composition of any one of claims 31~~32~~ to 51~~52~~, wherein the lubricant is stearic acid.

~~54.~~53. The pharmaceutical composition of any one of claims 31~~32~~ to 52~~53~~, wherein the amount of the lubricant is from ~~about~~ 2 to ~~about~~ 6 % w/w.

~~55.~~54. The pharmaceutical composition of claim 53~~54~~, wherein the amount of the lubricant is ~~about~~ 4 % w/w.

~~56.~~55. The pharmaceutical composition of any one of claims 31~~32~~ to 54~~55~~, wherein the disintegrant is sodium starch glycolate.

~~57.~~56. The pharmaceutical composition of claim 55~~56~~, wherein the amount of the disintegrant is from ~~about~~ 5 to ~~about~~ 15 % w/w.

~~58.~~57. The pharmaceutical composition of claim 56~~57~~, wherein the amount of the disintegrant is ~~about~~ 10 % w/w.

~~59.~~58. The pharmaceutical composition of claim 31~~32~~, comprising: 1) Compound 1 at an amount of ~~about~~ 0.13 % w/w; 2) partially pregelatinized starch at an amount of ~~about~~ 20 % w/w and anhydrous lactose at an amount of ~~about~~ 61.4 % w/w; 3) silica dimethyl silylate at an amount of ~~about~~ 0.5 % w/w; 4) fumaric acid at an amount of ~~about~~ 4 % w/w; 5) stearic acid at an amount of ~~about~~ 4 % w/w; and 6) sodium starch glycolate at an amount of ~~about~~ 10 % w/w.

~~60.~~59. The pharmaceutical composition of claim 58~~59~~, having a total weight of ~~about~~ 75 mg.

~~61.~~60. The pharmaceutical composition of claim 59~~60~~, which is contained in a size 4 capsule.

~~62.~~61. The pharmaceutical composition of claim 31~~32~~, comprising: 1) Compound 1 at an amount of ~~about~~ 0.5 % w/w; 2) partially pregelatinized starch at an amount of ~~about~~ 19.5 % w/w and anhydrous lactose at an amount of ~~about~~ 61 % w/w; 3) colloidal silicon dioxide at an amount of ~~about~~ 1 % w/w; 4) fumaric acid at an amount of ~~about~~ 4 % w/w; 5) stearic acid at an amount of ~~about~~ 4 % w/w; and 6) sodium starch glycolate at an amount of ~~about~~ 10 % w/w.

~~63.~~62. The pharmaceutical composition of claim 61~~62~~, having a total weight of ~~about~~ 100 mg.

~~64.~~63. The pharmaceutical composition of claim 62~~63~~, which is contained in a size 3 capsule.

~~65.~~64. The pharmaceutical composition of claim 31~~32~~, comprising: 1) Compound 1 at an amount of ~~about~~ 1 % w/w; 2) partially pregelatinized starch at an amount of ~~about~~ 19 % w/w and anhydrous lactose at an amount of ~~about~~ 61 % w/w; 3) colloidal silicon dioxide at an amount of ~~about~~ 1 % w/w; 4) fumaric acid at an amount of ~~about~~ 4 % w/w; 5) stearic acid at an amount of ~~about~~ 4 % w/w; and 6) sodium starch glycolate at an amount of ~~about~~ 10 % w/w.

~~66.~~65. The pharmaceutical composition of claim 64~~65~~, having a total weight of ~~about~~ 200 mg.

~~67.~~66. The pharmaceutical composition of claim 65~~66~~, which is contained in a size 2 capsule.

~~68.~~67. Use of a pharmaceutical composition of any one of claims 1-~~67~~66 in the manufacture of a medicament for a method of treating multiple myeloma in a patient.

~~69.~~68. A process for preparing a pharmaceutical composition of any one of claims 1 to 66~~67~~, comprising coating Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, with a hydrophobic silica.

~~70.~~69. The process of claim 68~~69~~, wherein the coating is conducted by blending Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and the hydrophobic silica to form a binary blend, before blending with additional excipients.

~~71.~~70. The process of claim 68~~69~~ or 69~~70~~, wherein the hydrophobic silica is silica dimethyl silylate.